Taiping Chen at MD Anderson to Speak at 2nd Cancer Epigenetics Conference Nov 8-9, 2012 Boston, MA

San Diego, CA (PressExposure) September 20, 2012 -- Taiping Chen, Associate Professor of Molecular Carcinogenesis at the University of Texas MD Anderson Cancer Center will give a presentation on "DNA Methylation and Human Diseases" at the 2nd Cancer Epigenetics conference taking place on Nov 8-9, 2012 in Boston, MA.

DNA methylation is a key epigenetic modification involved in a variety of biological processes, such as gene regulation, genomic imprinting, X chromosome inactivation, and maintenance of genome integrity. Aberrant DNA methylation patterns are associated with human diseases, including cancer. DNA methylation patterns are established during early embryogenesis by the de novo DNA methyltransferases Dnmt3a and Dnmt3b. Genetic studies in mice have demonstrated that Dnmt3b is essential for embryogenesis and Dnmt3a is required for postnatal survival and for the establishment of germline imprints. Studies in recent years have identified Dnmt3a mutations in patients with hematological malignancies and Dnmt3b mutations in patients with ICF (Immunodeficiency, Centromeric instability, and Facial anomalies) syndrome. Dr. Chen's group is interested in understanding the molecular mechanisms by which these mutations lead to the diseases and will present their recent progress in this effort.

Dr. Chen obtained his PhD in 2000 from McGill University (Montreal, Quebec, Canada), where he characterized the biochemical properties and biological functions of the GSG/STAR family of RNA-binding proteins. He then did his postdoctoral training at Massachusetts General Hospital, Harvard Medical School. Supported by fellowships from the Human Frontier Science Program and Canadian Institutes of Health Research, he conducted research on how DNA methylation is regulated during mouse development. In early 2004, Dr. Chen was recruited to Novartis Institutes for Biomedical Research (Cambridge, Massachusetts, USA) as a research investigator and laboratory head. The research in his group focused on the interplays and cooperation between the DNA methylation and histone methylation machineries in a variety of biological processes, including embryogenesis, genomic imprinting, and stem cell functions. In September 2011, Dr. Chen moved to MD Anderson Cancer Center (Smithville, Texas, USA). His group is continuing their work on the roles of epigenetic modifiers in mammalian development and diseases, particularly cancer. He recently received the CPRIT Rising Star Award (2011).

GTC's 2nd Cancer Epigenetics conference, one of two parallel tracks of the Cancer Summit - Novel Approaches to Drug Discovery on November 8-9 in Boston, MA, is the only cancer epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics.

For more information, please visit http://www.gtcbio.com

About GTC

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Company Contact:
635 W. Foothill Blvd. Monrovia, CA 91016
Tel: (626) 256-6405
email: infogtcbio@gtcbio.com

Company Website:

Event Website:

Press Release Source: http://PressExposure.com/PR/GTC.html

Press Release Submitted On: September 20, 2012 at 8:24 pm
This article has been viewed 75796 time(s).